Skip to main content

Does acute treatment of dapagliflozin reduce cardiac infarct size through direct cardiac effects or reductions in blood glucose levels?

In a recent article in this Journal, Lahnwong and co-workers [1], reported that acute pre-treatment of dapagliflozin just 15 min before start LAD occlusion reduced infarct size to a large extent in Wistar rats. These results are remarkable considering that most studies examining acute treatment with a SGLT2 inhibitor reported no effect on cardiac infarct size; only following chronic treatment (> > 1 d) do SGLT2i’s significantly reduce infarct size [2]. The question therefore arises what sets this study apart?

The answers may be found in the anesthetic regimen: animals were anesthetized with Zoletil and xylazine [1]. It is known that α2-adrenergic agonists such as xylazine or medetomidine acutely raise blood glucose to hyperglycemic values [3, 4] in non-fasted animals, through inhibition of insulin release from pancreatic β cells. Numerous studies have demonstrated that hyperglycemia is strongly associated with increased infarct size [5]. We therefore postulate that the intravenously administered dapagliflozin quickly lowered the high blood glucose levels in these animals, thereby explaining the reduction in infarct size by dapagliflozin in this experimental condition. It is therefore unfortunate that no information is provided by the authors on blood glucose, insulin, and ketone levels. We believe that in the search of potential cardioprotective mechanisms of SGLT2i’s, the nutritional status of the animal (fed versus fasted) and the substrate and hormone levels in the blood during the intervention being studied, should always be reported when examining these most promising antidiabetic drugs.

Availability of data and materials

Not applicable.

References

  1. 1.

    Lhanwong S, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, Chattipakom S, Chattipakom N. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovasc Diabetol. 2020;19(1):91.

    Article  Google Scholar 

  2. 2.

    Andreadou I, Bell RM, Bøtker HE, Zuurbier CJ. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochim Biophys Acta Mol Basis Dis. 2020;1866(7):165770.

    CAS  Article  Google Scholar 

  3. 3.

    Saha JK, Xia J, Grondin JM, Engle SK, Jakubowski JA. Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanism and implications for preclinical models. Exp Biol Med. 2005;230:777–84.

    CAS  Article  Google Scholar 

  4. 4.

    Zuurbier CJ, Keijzers PJM, Koeman A, van Wezel HB, Hollmann MW. Anesthesia’s effects on plasma glucose and insulin and cardiac hexokinase at similar hemodynamics and without major surgical stress in rats. Anesth Analg. 2008;106:135–42.

    CAS  Article  Google Scholar 

  5. 5.

    Penna C, Andreadou I, Aragno M, Beauloye C, Bertrand L, Lazou A, Falcao-Pires I, Bell R, Zuurbier CJ, Pagliaro P, Hausenloy DJ. Effect of hyperglycemia and diabetes on acute myocardial ischemia-reperfusion injury and cardioprotection by ischemic conditioning protocols. Br J Pharmacol. 2020. https://doi.org/10.1111/bph.14993.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None

Funding

No funding is involved with this commentary.

Author information

Affiliations

Authors

Contributions

CJZ is the sole contributor of this publication. The author read and approved the final manuscript.

Corresponding author

Correspondence to Coert J. Zuurbier.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The author declare that he has no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zuurbier, C.J. Does acute treatment of dapagliflozin reduce cardiac infarct size through direct cardiac effects or reductions in blood glucose levels?. Cardiovasc Diabetol 19, 141 (2020). https://doi.org/10.1186/s12933-020-01119-z

Download citation

Keywords

  • SGLT2i
  • Hyperglycemia
  • Xylazine
  • Infarct size
  • Ischemia-reperfusion